Intraday Info: Alcobra Ltd (NASDAQ:ADHD) locked on 05/01/2017 at $2.39. It has average volume 387,739 whilst it totals volume 779,502. The company has EPS -0.83 and according to analysts next quarter EPS and next year estimate EPS will -0.28 and -0.95 respectively. And it total income 19.40 million.
Ownership Summary: Alcobra Ltd has total institutional ownership 63.15% while its total outstanding shares 28 millions that’s value of holdings $39 million.
Active Positions: In the latest year, ADHD 21 holders have raised its positions while it contains total 2,033,480 shares. And the strength of reduced positions holders and held positions holders are 22 and 8 respectively.
New and Sold Out Positions: In ADHD force of new positions holders 6 and it has total shares 671,106. And force of sold out positions holders 8 and it has 3,598,733 shares.
Comparison with Other Company: The Market Value of ADHD is $65,871 above from AbbVie Inc. market value which is $103M. Current Last Sale of ADHD is $2.39 below from ABBV current last sale which is $63.77.
Alcobra Ltd. makes a speciality of the improvement and commercialization of oral drug applicants. The business enterprise is specifically developing MDX (metadoxine), an onset/extended launch system of the chemical pyridoxine pyroglutamate, that is in phase III clinical trial for adults with attention deficit hyperactivity ailment (ADHD); in section II medical trial for pediatric with ADHD; and that’s completed segment II medical trial in adolescents and adults with Fragile X Syndrome.